Structure Therapeutics Inc. (NASDAQ:GPCR) Receives $85.67 Consensus PT from Brokerages

Shares of Structure Therapeutics Inc. (NASDAQ:GPCR) have earned a consensus recommendation of “Buy” from the seven brokerages that are presently covering the company, MarketBeat Ratings reports. Seven analysts have rated the stock with a buy recommendation. The average 1 year target price among brokerages that have issued ratings on the stock in the last year is $85.67.

Several equities analysts have recently commented on GPCR shares. Morgan Stanley initiated coverage on shares of Structure Therapeutics in a research report on Monday, September 23rd. They set an “overweight” rating and a $118.00 price target on the stock. HC Wainwright assumed coverage on Structure Therapeutics in a report on Wednesday, December 4th. They set a “buy” rating and a $80.00 target price on the stock. Finally, Cantor Fitzgerald reiterated an “overweight” rating and issued a $65.00 price target on shares of Structure Therapeutics in a report on Monday, September 23rd.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Wellington Management Group LLP lifted its stake in Structure Therapeutics by 2.9% in the third quarter. Wellington Management Group LLP now owns 7,769,771 shares of the company’s stock valued at $341,015,000 after buying an additional 221,851 shares during the last quarter. FMR LLC increased its holdings in shares of Structure Therapeutics by 6.7% in the 3rd quarter. FMR LLC now owns 6,128,444 shares of the company’s stock worth $268,977,000 after acquiring an additional 383,635 shares during the period. Janus Henderson Group PLC increased its holdings in shares of Structure Therapeutics by 18.0% in the 3rd quarter. Janus Henderson Group PLC now owns 3,956,878 shares of the company’s stock worth $173,623,000 after acquiring an additional 602,609 shares during the period. Driehaus Capital Management LLC lifted its position in Structure Therapeutics by 3.5% in the 2nd quarter. Driehaus Capital Management LLC now owns 2,577,136 shares of the company’s stock valued at $101,204,000 after purchasing an additional 86,833 shares during the last quarter. Finally, Federated Hermes Inc. boosted its stake in Structure Therapeutics by 6.6% during the 2nd quarter. Federated Hermes Inc. now owns 2,407,206 shares of the company’s stock valued at $94,531,000 after purchasing an additional 150,000 shares during the period. Institutional investors and hedge funds own 91.78% of the company’s stock.

Structure Therapeutics Price Performance

NASDAQ GPCR opened at $31.48 on Friday. The company has a market capitalization of $1.80 billion, a price-to-earnings ratio of -42.54 and a beta of -3.41. Structure Therapeutics has a 12 month low of $26.61 and a 12 month high of $62.74. The company’s fifty day moving average price is $35.95 and its two-hundred day moving average price is $39.17.

About Structure Therapeutics

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company’s lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.